第Ⅸ因子欠乏症治療の世界市場2017-2021...市場調査レポートについてご紹介

【英文タイトル】Global Factor IX Deficiency Treatment Market 2017-2021

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report
• Market overview
• Assumptions
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights
• Highlights

PART 05: Disease overview

PART 06: Pipeline analysis

PART 07: Market landscape
• Market overview
• Five forces analysis

PART 08: Market segmentation by disease type
• Global hemophilia B drugs market
• Global hemophilia B inhibitors market

PART 09: Market segmentation by type of therapy
• Recombinant therapies
• Plasma-derived therapies

PART 10: Market segmentation by type of disease management
• Prophylaxis
• On-demand therapy
• Inhibitor therapy

PART 11: Geographical segmentation
• Factor IX drugs market in Americas
• Factor IX drugs market in EMEA
• Factor IX drugs market in APAC

PART 12: Market drivers
• Shifting toward half-life drugs
• Special designations promote novel launches
• Growing pipeline with increased focus to meet unmet demand

PART 13: Impact of drivers

PART 14: Market challenges
• Emerging price war in the industry
• Low penetration rate
• Lack of complete remission
• High entry barriers

PART 15: Impact of drivers and challenges

PART 16: Market trends
• Increasing focus on gene therapy
• Increase in investments in the production and discovery
• Strategic initiatives should lead to consolidation

PART 17: Vendor landscape
• Competitive scenario

PART 18: Key vendor analysis
• Biogen
• CSL Behring
• Novo Nordisk
• Pfizer
• Shire

PART 19: Appendix
• List of abbreviations

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Process of gene therapy
Exhibit 03: Key buying criteria and customer segments of global factor IX deficiency treatment market
Exhibit 04: Key customer segments of factor IX deficiency treatment market
Exhibit 05: Pipeline analysis
Exhibit 06: Key clinical trials
Exhibit 07: Global factor IX deficiency treatment market snapshot
Exhibit 08: Global factor IX deficiency treatment market by revenue 2016-2021 ($ millions)
Exhibit 09: Five forces analysis
Exhibit 10: Hemophilia B drugs market for global factor IX deficiency treatment market 2016-2021 ($ millions)
Exhibit 11: Hemophilia B inhibitors market for global factor IX deficiency treatment market 2016-2021 ($ millions)
Exhibit 12: Global factor IX recombinant therapies market 2016-2021 ($ millions)
Exhibit 13: Global factor IX plasma-derived therapies market 2016-2021 ($ millions)
Exhibit 14: Segmentation of factor IX drugs market by type of disease management 2016
Exhibit 15: Factor IX deficiency treatment market in Americas 2016-2021 ($ millions)
Exhibit 16: Factor IX deficiency treatment market in EMEA 2016-2021 ($ millions)
Exhibit 17: Factor IX deficiency treatment market in APAC 2016-2021($ millions)
Exhibit 18: Launch of half-life drugs for treatment of factor IX deficiency
Exhibit 19: Special designation to factor IX drugs in 2016
Exhibit 20: A few late-stage (Phase III) factor IX drugs
Exhibit 21: Impact of drivers
Exhibit 22: Impact of drivers and challenges
Exhibit 23: Competitive structure of global factor IX deficiency treatment market 2016
Exhibit 24: Competitive analysis of global factor IX deficiency treatment market
Exhibit 25: Market share analysis 2016
Exhibit 26: Market penetration of factor IX vendors 2016
Exhibit 27: Biogen: Key highlights
Exhibit 28: Biogen: Strength assessment
Exhibit 29: Biogen: Strategy assessment
Exhibit 30: Biogen: Opportunity assessment
Exhibit 31: Year-over-year (YoY) revenue of ALPROLIX 2014-2016 ($ millions)
Exhibit 32: CSL Behring: Key highlights
Exhibit 33: CSL Behring: Strength assessment
Exhibit 34: CSL Behring: Strategy assessment
Exhibit 35: CSL Behring: Opportunity assessment
Exhibit 36: Novo Nordisk: Key highlights
Exhibit 37: Novo Nordisk: Strength assessment
Exhibit 38: Novo Nordisk: Strategy assessment
Exhibit 39: Novo Nordisk: Opportunity assessment
Exhibit 40: Pfizer: Key highlights
Exhibit 41: Pfizer: Strength assessment
Exhibit 42: Pfizer: Strategy assessment
Exhibit 43: Pfizer: Opportunity assessment
Exhibit 44: Shire: Key highlights
Exhibit 45: Shire: Strength assessment
Exhibit 46: Shire: Strategy assessment
Exhibit 47: Shire: Opportunity assessment
Exhibit 48: Shire: YoY revenue comparison of RIXUBIS 2014 and 2015 ($ millions)


【レポート販売概要】

■ タイトル:第Ⅸ因子欠乏症治療の世界市場2017-2021
■ 英文:Global Factor IX Deficiency Treatment Market 2017-2021
■ 発行日:2017年3月7日
■ 調査会社:Technavio
■ 商品コード:IRTNTR12153
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。